CN108837121A - 一种治疗高尿酸的中药组合物及其制备方法 - Google Patents
一种治疗高尿酸的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN108837121A CN108837121A CN201811016114.XA CN201811016114A CN108837121A CN 108837121 A CN108837121 A CN 108837121A CN 201811016114 A CN201811016114 A CN 201811016114A CN 108837121 A CN108837121 A CN 108837121A
- Authority
- CN
- China
- Prior art keywords
- parts
- fine powder
- medicinal extract
- powder mixture
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 244000281702 Dioscorea villosa Species 0.000 claims abstract description 22
- 241000234435 Lilium Species 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 241000601164 Clematis orientalis Species 0.000 claims abstract description 11
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 11
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 11
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 11
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 11
- 240000000249 Morus alba Species 0.000 claims abstract description 11
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 11
- 241000205407 Polygonum Species 0.000 claims abstract description 11
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 11
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 11
- 235000000485 Smilax china Nutrition 0.000 claims abstract description 11
- 240000009022 Smilax rotundifolia Species 0.000 claims abstract description 11
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims abstract description 11
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 11
- 235000013976 turmeric Nutrition 0.000 claims abstract description 11
- 241000605422 Asparagus asparagoides Species 0.000 claims abstract description 9
- 241001499733 Plantago asiatica Species 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 90
- 239000000284 extract Substances 0.000 claims description 87
- 239000000843 powder Substances 0.000 claims description 75
- 235000019441 ethanol Nutrition 0.000 claims description 42
- 239000000706 filtrate Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 239000000463 material Substances 0.000 claims description 26
- 239000000470 constituent Substances 0.000 claims description 25
- 230000006837 decompression Effects 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 22
- 230000004913 activation Effects 0.000 claims description 16
- 238000004064 recycling Methods 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 11
- 235000020357 syrup Nutrition 0.000 claims description 11
- 239000006188 syrup Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 235000008216 herbs Nutrition 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 238000005057 refrigeration Methods 0.000 claims description 7
- 229940100688 oral solution Drugs 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 238000002386 leaching Methods 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 47
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 47
- 229940116269 uric acid Drugs 0.000 abstract description 47
- 230000000694 effects Effects 0.000 abstract description 33
- 201000005569 Gout Diseases 0.000 abstract description 7
- 210000002966 serum Anatomy 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 238000001914 filtration Methods 0.000 description 19
- 201000010099 disease Diseases 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 10
- 244000298479 Cichorium intybus Species 0.000 description 9
- 235000007542 Cichorium intybus Nutrition 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
- 235000007516 Chrysanthemum Nutrition 0.000 description 8
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 7
- -1 filtration Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 238000007605 air drying Methods 0.000 description 6
- 229960003459 allopurinol Drugs 0.000 description 6
- 229940126678 chinese medicines Drugs 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 108010093894 Xanthine oxidase Proteins 0.000 description 4
- 102100033220 Xanthine oxidase Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 3
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 201000001431 Hyperuricemia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- OEGPRYNGFWGMMV-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C=C1OC OEGPRYNGFWGMMV-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Chemical class 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229920001223 polyethylene glycol Chemical class 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WNBCMONIPIJTSB-TVKJYDDYSA-N Cichoriin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1C=CC(=O)O2 WNBCMONIPIJTSB-TVKJYDDYSA-N 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Chemical class 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000362909 Smilax <beetle> Species 0.000 description 1
- 244000113428 Sonchus oleraceus Species 0.000 description 1
- 235000006745 Sonchus oleraceus Nutrition 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- SFCXYSXJRRDDNZ-UHFFFAOYSA-N [N].N1C(=O)NC(=O)C2=C1NC(=O)N2 Chemical compound [N].N1C(=O)NC(=O)C2=C1NC(=O)N2 SFCXYSXJRRDDNZ-UHFFFAOYSA-N 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000006193 cichoric acid Nutrition 0.000 description 1
- 229930016920 cichoric acid Natural products 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Chemical class 0.000 description 1
- 229920000159 gelatin Chemical class 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VJQAFLAZRVKAKM-QQUHWDOBSA-N lactucin Chemical compound O[C@@H]1CC(C)=C2C(=O)C=C(CO)[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 VJQAFLAZRVKAKM-QQUHWDOBSA-N 0.000 description 1
- VJQAFLAZRVKAKM-UHFFFAOYSA-N lactucine Natural products OC1CC(C)=C2C(=O)C=C(CO)C2C2OC(=O)C(=C)C21 VJQAFLAZRVKAKM-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗高尿酸的中药组合物及其制备方法。本发明选择兰菊根、土茯苓、虎杖、菝葜、姜黄、粉萆薢、栀子、车前草、威灵仙、秦艽、桑叶、葛根、百合作为原料,按配比组合,按照一定的工艺,加工成成品,患者服用后能有效促进尿酸代谢,降低血尿酸浓度的作用,明显减少痛风复发,且能增强患者体质,安全有效,没有副作用,并且生产成本低廉,简便易用,便于推广,环保,安全,健康和有效。
Description
技术领域
本发明涉及中医中药技术领域,特别涉及一种治疗高尿酸的中药组合物及其制备方法和使用方法。
背景技术
随着经济的发展和饮食习惯的改变,现代生活节奏快、压力大,平时工作往往又不注意身体健康状况,在体检的时候就会发现各种问题,尿酸高就是比较多见的,高尿酸症发病率呈现上升的趋势,我国现有高尿酸症患者已经达到九千万,高尿酸症与嘌呤代谢紊乱和尿酸排泄减少有关。高尿酸症易在组织中形成结晶,可以有5%--12%造成痛风,也有研究表明,高尿酸症还与很多慢性病如糖尿病、肥胖、心血管病、高血压、高血脂、代谢综合征、肾脏疾病有内在关联。目前,临床上采用西药降尿酸药物,如秋水仙碱、非布索坦、别嘌醇以及一些止痛药,这些药物虽然有作用,但是副作用太大,长期服用,易造成肾脏、肝脏损伤和骨髓抑制,并刺激胃肠道带来的副作用让患者苦不堪言。因此,发明一种治疗高尿酸的中药组合物及其制备方法来解决上述问题很有必要。
发明内容
基于上述技术背景,本发明的目的在于针对现有技术的不足,提供一种治疗高尿酸的中药组合物及其制备方法。本发明对于治疗高尿酸症,降低高尿酸具有显著疗效,无副作用,服用方便,价格低廉,以解决上述背景技术中提出的技术难题。
本发明创新地把13种中药材组合在一起,配以合理的粒度配比,超声波振动等先进的工艺流程,还结合科学配伍达到自然治疗高尿酸的药效,并且生产成本低廉,简便易用,便于推广,环保,安全,健康和有效。
为了实现上述目的,本发明是通过如下的技术方案来实现:
一种治疗高尿酸的中药组合物,包括以下重量份数的药材成分:兰菊根8-16份、土茯苓10-20份、虎杖6-12份、菝葜8-14份、姜黄6-12份、粉萆薢10-16份、栀子4-8份、车前草6-12份、威灵仙4-10份、秦艽8-14份、桑叶2-6份、葛根6-12份、百合2-6份。
本发明这种治疗高尿酸的中药组合物的制备方法为:
步骤一、将这13种中药原材料分别以单品精选、清洗、净化、风干,再按重量份数进行混合, 并粉碎成细粉,得到细粉混合物,细粉混合物的粒度为0.0001mm—0.044mm,0.044mm—0.074mm ,0.074 mm-1mm,1 mm-3mm中的两个或两个以上的粒度区间,把细粉混合物分成三份,备用;
步骤二、把步骤一得到的第一份细粉混合物, 投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第一份细粉混合物总重量的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时,得到相对密度为1.05-1.25的第一份浸膏;
步骤三、把步骤一得到的第二份细粉混合物,投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第二份细粉混合物的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时, 得到相对密度为1.10-1.20的浸膏,冷却,加入4倍量的乙醇,充分搅拌,静置冷藏12-24小时,滤过,滤液回收乙醇后,滤液减压浓缩至70-80℃时,相对密度为1.15-1.30的第二份浸膏;
步骤四、把步骤一得到的第三份细粉混合物,用40-80%乙醇回流提取2次,每次乙醇用量为第三份细粉混合物的4-10倍,提取时间为1-2小时,合并提取液,滤过,滤液回收乙醇后,滤液减压浓缩至60-80℃时,得到相对密度为1.20-1.35的第三份浸膏;
步骤五、把第一份、第二份、第三份浸膏进行混合, 搅拌均匀, 得到具有治疗高尿酸的活性成分浸膏;
步骤六、片剂的制备方法;取步骤五得到的活性成分浸膏,加入片剂常用辅料,按常规生产方法制备得到本发明片剂;
步骤七、颗粒剂制备方法;取步骤五得到的活性成分浸膏,加入颗粒剂常用辅料,按常规生产方法制备得本发明颗粒剂;
步骤八、胶囊剂制备方法;取步骤五得到的活性成分浸膏,加入胶囊剂常用辅料,按常规生产方法制备得本发明胶囊剂;
步骤九、糖浆剂制备方法;取步骤五得到的活性成分浸膏,加入糖浆剂常用辅料,按常规生产方法制备得本发明糖浆剂;
步骤十、囗服液制备方法;取步骤五得到的活性成分浸膏,溶解后净化、浓缩,加入囗服液常用辅料,按常规生产方法制备得本发明囗服液。
其中囗服液常用辅料包括矫味剂、防腐剂、助溶剂之一或全部。
其中步骤一中细粉混合物的粒度为0.0001mm—0.044mm,0.044mm—0.074mm ,0.074 mm-1mm,1 mm-3mm中的两个或两个以上的粒度区间,
本发明,并不是一味把13种中药材,粉碎成一个粒度区间,而是几个粒度区间,每个粒度区间分别有不同的药用成分的溢出,这样能更好的提取中药材中的药用成分,对于一些材质硬的药材,适合粒度小一些, 可以使原材料中的细胞内的有效成分全部充分释放出来,从而提高材料的生物利用度,对于一些材质软的药材, 适合粒度大一些,更便于后续工艺的提取和加工,因此本发明综合了这13种中药材的特性,确定了细粉混合物的粒度分布。
其中步骤二和步骤三中分别使用了超声波振动,是为了将中药食材的细胞壁打破,让其释放细胞内部的药用物质。
本发明并不是一味把13种中药材用一种方法来提取,而是用了3种不同方法来提取,这样可以让隐含在中药材中不同的药效在每个工艺阶段,最大程度的溢出。
本发明从这13种中药材的颗粒中用特定的工艺制备出了浸膏,而不是制备提取液和其他形式的提取物,这是因为浸膏能把这13种中药材的活性成分和药用成分完全囊括和包含,可使最终产品具有强有效的药效。
其中片剂常用辅料包括稀释剂、润湿剂、粘合剂、崩解剂、润滑剂之一或全部。
其中颗粒剂常用辅料包括稀释剂、润湿剂、粘合剂、崩解剂之一或全部。
其中胶囊剂常用辅料包括稀释剂、润湿剂、粘合剂、崩解剂、润滑剂之一或全部。
其中糖浆剂常用辅料包括矫味剂、防腐剂、助溶剂之一或全部。
本发明的药学上可接受的载体包括,但不限于以下:
稀释剂:淀粉、糖粉、乳糖、糊精、微晶纤维素、无机盐、糖醇类等。
湿润剂与粘合剂:纯化水、乙醇、明胶、聚乙二醇、纤维素衍生物等。
崩解剂:淀粉、羧甲基淀粉钠、纤维素衍生物、交联聚维酮等。
润滑剂:硬脂酸镁、微粉硅胶、滑石粉、聚乙二醇等。
助溶剂:水、乙醇、甘油、丙二醇、液体石蜡、植物油等。
矫味剂:蔗糖、单糖浆、芳香剂、蜂蜜、甘草酸和甜菊苷等。
防腐剂:苯甲酸、山梨酸、丙酸、甲酯、乙酯、丙酯等。
本发明的技术有益效果和优点:
本发明选择兰菊根、土茯苓、虎杖、菝葜、姜黄、粉萆薢、栀子、车前草、威灵仙、秦艽、桑叶、葛根、百合作为原料,按配比组合,按照一定的工艺,加工成成品,患者服用后能有效促进尿酸代谢,降低血尿酸浓度的作用,明显减少痛风复发,且能增强患者体质,安全有效,没有副作用。
临床试验结果显示,治疗3个月后,采用本发明中药配方能够改善高尿酸缓解期患者临床证候,对高尿酸缓解期患者有效率达93.6%,与对照组比有显著性差异。
本发明中13种中药的作用:
兰菊根:为菊科植物菊苣的地上部分,兰菊根别名菊苣、苦苣,菊苣味苦,性寒;清热解毒,利尿消肿。兰菊根的作用是治湿热黄疸、肾炎水肿。菊苣降尿酸活性成分可能为绿原酸、秦皮甲素、菊苣酸,其发挥的降尿酸机制可能与抑制黄嘌呤氧化酶、腺苷脱氨酶活性有关。菊苣根含有苦味物质的成分有马栗树皮素、马栗树皮甙、野莴苣甙、山莴苣素和山莴苣苦素等,有清肝利胆的功效。莴苣素有镇痛和催眠作用。马栗树皮甙等对高血压、高血脂等病症有着显著的药用价值。因此菊苣也被称为—痛风的克星。菊苣兼具食用和药用两种功用的特殊植物,现已被卫生部列为“药食同源类”食品,同时被国家营养联盟专家誉为“健康之王”。菊苣本身所含的多种营养成分,使得它具有改善人体血清尿酸水平。研究证明菊苣有效成分可显著降低由高血糖引发的尿酸、血糖升高,并综合调节脂、糖、尿酸交互紊乱的作用。菊苣提取物可明显改善由高嘌呤饮食引发的高尿酸血症及腹型肥胖,从而发挥综合调节尿酸及腹部脂肪堆积的作用。
土茯苓:性味甘淡,平;归胃、肝、脾经。解毒,除湿,利关节。动物研究实验显示,土茯苓有降尿酸作用,同时其利湿作用也有助于尿酸的排泄。
虎杖:性味微苦,微寒;归旰、胆、肺经。利湿退黄,清热解毒,散瘀止痛。有研究显示虎杖醇提液对高尿酸血症小鼠有降尿酸作用。
菝葜:性味酸,涩;归肝、肾经。祛风利湿,解毒消痈。研究表明,菝葜的有效成分白藜芦醇具有降尿酸作用,白藜芦醇可竞争性抑制黄嘌呤氧化酶。
姜黄:性味辛苦,温;归脾、肝经。破血,行气,通经,止痛。研究表明姜黄高剂量醇提取物具有降低尿酸、抑制黄嘌呤氧化酶活性、促进尿夜尿酸排泄的作用。
粉萆薢:性味苦,平;归肝、胃、膀胱经。利湿去浊,祛风通痹。动物研究结果显示高剂量粉萆薢水提物能显著降低小鼠和大鼠血清尿酸含量。
栀子:味苦,性寒;归心、肝、肺、胃经。清热,泻火,凉血。栀子乙酸乙酯提取物和水液提取物为降尿酸活性成分,其降尿酸作用部分机制是通过抑制黄嘌呤氧化酶的活性。
车前草:味甘,性寒;归肝、肾、肺、小肠经。清热利尿,祛痰,凉血,解毒。车前草的降尿酸作用是由于其利尿作用,可促进体内的尿酸通过尿液排出。
威灵仙:味辛、咸,性温,有毒。归膀胱经。祛风除湿,通络止痛。威灵仙具有溶解尿酸盐作用,从而降低尿酸。
秦艽:味辛、苦,性微寒;归胃、肝、胆经。祛风湿,舒筋络,清虚热。现代药理证明秦艽具有非常好的降尿酸效果,其主要通过抑制尿酸生成和促进尿酸排泄这两个途径来实现的。
桑叶:桑叶总黄酮可显著降低尿酸水平,与别嘌醇的降尿酸效果相当;并能显著降低尿酸氮、肌肝、丙二醛、甘油三酯、游离脂肪酸水平和肝脏系数、肾脏系数。
葛根:葛根提取物具有抗痛风性关节炎的作用,能缓解MSU急性痛风性关节炎模型大鼠的关节肿胀情况,缓解由于炎症引起的脾肿大及肾损伤作用,并降低血清UA水平。
百合:百合含有治疗痛风的特效成分—秋水仙碱。秋水仙碱可抑制白细胞的趋化作用,从而改善关节炎症状。百合还有利尿作用,可促进尿酸的排泄。由于百合中秋水仙碱的含量有限,需长期服用才能够发挥其治疗功效。
具体实施方式:
下面通过实施例进一步说明本发明。应该理解的是,本发明的实施例是用于说明本发明而不是对本发明的限制。根据本发明的实质对本发明进行的简单改进都属于本发明要求保护的范围。
实施例1片剂:
兰菊根16份、土茯苓20份、虎杖12份、菝葜14份、姜黄12份、粉萆薢16份、栀子8份、车前草12份、威灵仙10份、秦艽14份、桑叶6份、葛根12份、百合6份。
制备方法为:
步骤一、将这13种中药原材料分别以单品精选、清洗、净化、风干,再按重量份数进行混合, 并粉碎成细粉,得到细粉混合物,细粉混合物的粒度为0.0001mm—0.044mm,0.044mm—0.074mm ,0.074 mm-1mm,1 mm-3mm中的两个或两个以上的粒度区间,把细粉混合物分成三份,备用;
步骤二、把步骤一得到的第一份细粉混合物, 投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第一份细粉混合物总重量的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时,得到相对密度为1.05-1.25的第一份浸膏;
步骤三、把步骤一得到的第二份细粉混合物,投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第二份细粉混合物的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时, 得到相对密度为1.10-1.20的浸膏,冷却,加入4倍量的乙醇,充分搅拌,静置冷藏12-24小时,滤过,滤液回收乙醇后,滤液减压浓缩至70-80℃时,相对密度为1.15-1.30的第二份浸膏;
步骤四、把步骤一得到的第三份细粉混合物,用40-80%乙醇回流提取2次,每次乙醇用量为第三份细粉混合物的4-10倍,提取时间为1-2小时,合并提取液,滤过,滤液回收乙醇后,滤液减压浓缩至60-80℃时,得到相对密度为1.20-1.35的第三份浸膏;
步骤五、把第一份、第二份、第三份浸膏进行混合, 搅拌均匀, 得到具有治疗高尿酸的活性成分浸膏;
步骤六、片剂的制备方法;取步骤五得到的活性成分浸膏,加入辅料料淀粉、乙醇、滑石粉,制得片剂。
实施例2颗粒剂:
兰菊根14份、土茯苓18份、虎杖10份、菝葜12份、姜黄10份、粉萆薢14份、栀子7份、车前草10份、威灵仙8份、秦艽12份、桑叶5份、葛根10份、百合5份。
制备方法为:
步骤一、将这13种中药原材料分别以单品精选、清洗、净化、风干,再按重量份数进行混合, 并粉碎成细粉,得到细粉混合物,细粉混合物的粒度为0.0001mm—0.044mm,0.044mm—0.074mm ,0.074 mm-1mm,1 mm-3mm中的两个或两个以上的粒度区间,把细粉混合物分成三份,备用;
步骤二、把步骤一得到的第一份细粉混合物, 投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第一份细粉混合物总重量的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时,得到相对密度为1.05-1.25的第一份浸膏;
步骤三、把步骤一得到的第二份细粉混合物,投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第二份细粉混合物的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时, 得到相对密度为1.10-1.20的浸膏,冷却,加入4倍量的乙醇,充分搅拌,静置冷藏12-24小时,滤过,滤液回收乙醇后,滤液减压浓缩至70-80℃时,相对密度为1.15-1.30的第二份浸膏;
步骤四、把步骤一得到的第三份细粉混合物,用40-80%乙醇回流提取2次,每次乙醇用量为第三份细粉混合物的4-10倍,提取时间为1-2小时,合并提取液,滤过,滤液回收乙醇后,滤液减压浓缩至60-80℃时,得到相对密度为1.20-1.35的第三份浸膏;
步骤五、把第一份、第二份、第三份浸膏进行混合, 搅拌均匀, 得到具有治疗高尿酸的活性成分浸膏;
步骤六、颗粒剂制备方法;取步骤五得到的活性成分浸膏,加入辅料糖粉、淀粉、糊精、乙醇,制得颗粒剂。
实施例3胶囊剂:
兰菊根16份、土茯苓18份、虎杖10份、菝葜10份、姜黄8份、粉萆薢12份、栀子6份、车前草9份、威灵仙8份、秦艽10份、桑叶4份、葛根10份、百合4份。
制备方法为:
步骤一、将这13种中药原材料分别以单品精选、清洗、净化、风干,再按重量份数进行混合, 并粉碎成细粉,得到细粉混合物,细粉混合物的粒度为0.0001mm—0.044mm,0.044mm—0.074mm ,0.074 mm-1mm,1 mm-3mm中的两个或两个以上的粒度区间,把细粉混合物分成三份,备用;
步骤二、把步骤一得到的第一份细粉混合物, 投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第一份细粉混合物总重量的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时,得到相对密度为1.05-1.25的第一份浸膏;
步骤三、把步骤一得到的第二份细粉混合物,投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第二份细粉混合物的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时, 得到相对密度为1.10-1.20的浸膏,冷却,加入4倍量的乙醇,充分搅拌,静置冷藏12-24小时,滤过,滤液回收乙醇后,滤液减压浓缩至70-80℃时,相对密度为1.15-1.30的第二份浸膏;
步骤四、把步骤一得到的第三份细粉混合物,用40-80%乙醇回流提取2次,每次乙醇用量为第三份细粉混合物的4-10倍,提取时间为1-2小时,合并提取液,滤过,滤液回收乙醇后,滤液减压浓缩至60-80℃时,得到相对密度为1.20-1.35的第三份浸膏;
步骤五、把第一份、第二份、第三份浸膏进行混合, 搅拌均匀, 得到具有治疗高尿酸的活性成分浸膏;
步骤六、胶囊剂制备方法;取步骤五得到的活性成分浸膏,加入辅料淀粉、乙醇、糊精、硬脂酸镁,装入胶囊壳,制得胶囊剂。
实施例4囗服液:
兰菊根15份、土茯苓18份、虎杖11份、菝葜12份、姜黄9份、粉萆薢13份、栀子5份、车前草10份、威灵仙9份、秦艽11份、桑叶5份、葛根9份、百合5份。
制备方法为:
步骤一、将这13种中药原材料分别以单品精选、清洗、净化、风干,再按重量份数进行混合, 并粉碎成细粉,得到细粉混合物,细粉混合物的粒度为0.0001mm—0.044mm,0.044mm—0.074mm ,0.074 mm-1mm,1 mm-3mm中的两个或两个以上的粒度区间,把细粉混合物分成三份,备用;
步骤二、把步骤一得到的第一份细粉混合物, 投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第一份细粉混合物总重量的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时,得到相对密度为1.05-1.25的第一份浸膏;
步骤三、把步骤一得到的第二份细粉混合物,投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第二份细粉混合物的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时, 得到相对密度为1.10-1.20的浸膏,冷却,加入4倍量的乙醇,充分搅拌,静置冷藏12-24小时,滤过,滤液回收乙醇后,滤液减压浓缩至70-80℃时,相对密度为1.15-1.30的第二份浸膏;
步骤四、把步骤一得到的第三份细粉混合物,用40-80%乙醇回流提取2次,每次乙醇用量为第三份细粉混合物的4-10倍,提取时间为1-2小时,合并提取液,滤过,滤液回收乙醇后,滤液减压浓缩至60-80℃时,得到相对密度为1.20-1.35的第三份浸膏;
步骤五、把第一份、第二份、第三份浸膏进行混合, 搅拌均匀, 得到具有治疗高尿酸的活性成分浸膏;
步骤六、囗服液制备方法;取步骤五得到的活性成分浸膏,加入辅料蜂蜜、单糖苷、苯甲酸,搅匀滤过后,分装,灭菌,制得口服液。
实施例5糖浆剂:
兰菊根8份、土茯苓10份、虎杖6份、菝葜8份、姜黄6份、粉萆薢10份、栀子4份、车前草6份、威灵仙4份、秦艽8份、桑叶2份、葛根6份、百合2份。
制备方法为:
步骤一、将这13种中药原材料分别以单品精选、清洗、净化、风干,再按重量份数进行混合, 并粉碎成细粉,得到细粉混合物,细粉混合物的粒度为0.0001mm—0.044mm,0.044mm—0.074mm ,0.074 mm-1mm,1 mm-3mm中的两个或两个以上的粒度区间,把细粉混合物分成三份,备用;
步骤二、把步骤一得到的第一份细粉混合物, 投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第一份细粉混合物总重量的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时,得到相对密度为1.05-1.25的第一份浸膏;
步骤三、把步骤一得到的第二份细粉混合物,投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第二份细粉混合物的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时, 得到相对密度为1.10-1.20的浸膏,冷却,加入4倍量的乙醇,充分搅拌,静置冷藏12-24小时,滤过,滤液回收乙醇后,滤液减压浓缩至70-80℃时,相对密度为1.15-1.30的第二份浸膏;
步骤四、把步骤一得到的第三份细粉混合物,用40-80%乙醇回流提取2次,每次乙醇用量为第三份细粉混合物的4-10倍,提取时间为1-2小时,合并提取液,滤过,滤液回收乙醇后,滤液减压浓缩至60-80℃时,得到相对密度为1.20-1.35的第三份浸膏;
步骤五、把第一份、第二份、第三份浸膏进行混合, 搅拌均匀, 得到具有治疗高尿酸的活性成分浸膏;
步骤六、糖浆剂制备方法;取步骤五得到的活性成分浸膏,在浸膏中加入糖浆剂辅料蔗糖、山梨酸、水搅拌均匀,制得糖浆剂。
本发明中药配方无副作用,使用方便,价格低廉,根据临床300例观察统计,实施例1-5中药组合物的总有效率为93.6%。
本发明降尿酸的临床效果资料:
一、高尿酸症的分级
尿酸是体内核酸中嘌呤分解的最终产物,大部分经肾脏排出。当肾功能受损伤时,尿酸易潴留于血中而导致血中含量升高,在肾脏病变早期,血中尿酸浓℃常首先升高,所以此项指标有助于较早期地诊断肾脏的病变,从临床角℃来看,已发痛风者,尿酸含量可升高;急慢性肾小球肾炎,一般伴有血清尿酸增高。一般来说,高尿酸病人主要常见于经常性大量进食含有嘌呤成分丰富的食物,同时肥胖人群,高血压高血脂人群居多。
对于男性来说,尿酸值在416umol/L—500umol/L患者为1级高尿酸症,尿酸值在500umol/L—600umol/L患者为2级高尿酸症,尿酸值在600umol/L以上的患者为3级高尿酸症。
对于女性来说,尿酸值在357umol/L—450umol/L患者为1级高尿酸症,尿酸值在450umol/L—550umol/L患者为2级高尿酸症,尿酸值在550umol/L以上的患者为3级高尿酸症。
二、疗效判断标准:
1.完全缓解:对于男性来说,尿酸值降到416umol/L以下判为完全缓解;对于女性来说,尿酸值降到357umol/L以下判为完全缓解。
2.基本缓解:对于男性来说,尿酸值降到了100umol/L判为基本缓解;对于女性来说,尿酸值降到了80umol/L判为基本缓解。
3.好转:对于男性来说,尿酸值降到了50umol/L判为好转;对于女性来说,尿酸值降到了40umol/L判为好转。
4.无效:对于男性来说,尿酸值降到了10umol/L左右判为无效;对于女性来说,尿酸值降到了8umol/L判为无效。
临床治疗效果:
一、临床效果
本发明组男性75例,女性75例,平均年龄45---56岁。经中医诊断均为湿热蕴结症型、湿热困脾型。
治疗组,使用本发明中药配方,使用时间为15天,剂量12g颗粒剂一袋,用温开水送服,一天两次,男性45例,显效34例(75.56%),有效10例(22.22%),无效1例(2.22%),总有效率达97.78%;对照组男性30例,使用西药别嘌醇,剂量按说明书使用,显效21例(70%),有效7例(23.33%),无效2例(6.67%),西药别嘌醇总有效率(93.33%)。可以看出本发明组与西药别嘌醇组的尿酸水平,组别差异不显著。提示,本发明中药配方组与西药别嘌醇组都有较好的疗效,但本发明中药组没有副作用。
在女性高尿酸患者治疗效果分析:治疗组,使用本发明中药配方,使用时间为15天,剂量12g颗粒剂一袋,用温开水送服,一天两次。46例,显效37例(80.43%),有效7例(15.22%),无效2例(4.35%),总有效率达95.65%;对照组29例,使用西药别嘌醇,剂量按说明书使用,显效24例(82.76%),有效3例(10.34%),无效2例(6.90%),总有效率达93.10%。可以看出,本发明组治疗与西药别嘌醇治疗组都有较好降尿酸水平的作用,但组别差异不显著,但是本发明中药组没有副作用。
二、典型临床病例:
1.黄某,女,38岁,河南辉县市张村镇,职工,体检中查出尿酸为426,来辉县市中医院就诊,经中医诊断为湿热困脾型,经复查,发现尿酸为431,血脂2.32,诊断为高尿酸症,高血脂症,服用本发明中药配方15天后,再次检查,尿酸401,血脂1.21,判断已正常,医嘱少吃动物内脏、海鲜,三个月后,再次复査,尿酸和血脂都正常。
2.吴某,男,48岁,河南辉县市常村人,司机,查体右足第一跖趾可见痛风石形成,且红肿、触痛,血尿酸614,尿尿酸320,诊断高尿酸症。服用本发明中药配方三个月,血尿酸380,尿尿酸210,疼痛感明显减轻,医嘱注意饮食并减量继续服用一个月再复查。
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包括在本发明的保护范围之内。
Claims (3)
1.一种治疗高尿酸的中药组合物,其特征在于:包括以下重量份数的药材成分:兰菊根8-16份、土茯苓10-20份、虎杖6-12份、菝葜8-14份、姜黄6-12份、粉萆薢10-16份、栀子4-8份、车前草6-12份、威灵仙4-10份、秦艽8-14份、桑叶2-6份、葛根6-12份、百合2-6份。
2.根据权利要求1所述的一种治疗高尿酸的中药组合物的制备方法,其特征在于:步骤一、将这13种中药原材料分别以单品精选、清洗、净化、风干,再按重量份数进行混合, 并粉碎成细粉,得到细粉混合物,把细粉混合物分成三份,备用;步骤二、把步骤一得到的第一份细粉混合物, 投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第一份细粉混合物总重量的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时,得到相对密度为1.05-1.25的第一份浸膏;步骤三、把步骤一得到的第二份细粉混合物,投入提取罐中,用12倍水浸泡12小时,进行超声波振动45分钟,100℃保持沸腾1-2小时,提取2次,每次加水量相当于第二份细粉混合物的12倍,合并提取液,滤过,滤液减压浓缩至70-80℃时, 得到相对密度为1.10-1.20的浸膏,冷却,加入4倍量的乙醇,充分搅拌,静置冷藏12-24小时,滤过,滤液回收乙醇后,滤液减压浓缩至70-80℃时,相对密度为1.15-1.30的第二份浸膏;步骤四、把步骤一得到的第三份细粉混合物,用40-80%乙醇回流提取2次,每次乙醇用量为第三份细粉混合物的4-10倍,提取时间为1-2小时,合并提取液,滤过,滤液回收乙醇后,滤液减压浓缩至60-80℃时,得到相对密度为1.20-1.35的第三份浸膏;步骤五、把第一份、第二份、第三份浸膏进行混合, 搅拌均匀, 得到具有治疗高尿酸的活性成分浸膏;步骤六、片剂的制备方法;取步骤五得到的活性成分浸膏,加入片剂常用辅料,按常规生产方法制备得到本发明片剂;步骤七、颗粒剂制备方法;取步骤五得到的活性成分浸膏,加入颗粒剂常用辅料,按常规生产方法制备得本发明颗粒剂;
步骤八、胶囊剂制备方法;取步骤五得到的活性成分浸膏,加入胶囊剂常用辅料,按常规生产方法制备得本发明胶囊剂;步骤九、糖浆剂制备方法;取步骤五得到的活性成分浸膏,加入糖浆剂常用辅料,按常规生产方法制备得本发明糖浆剂;步骤十、囗服液制备方法;取步骤五得到的活性成分浸膏,溶解后净化、浓缩,加入囗服液常用辅料,按常规生产方法制备得本发明囗服液。
3.根据权利要求2所述的一种治疗高尿酸的中药组合物的制备方法,其特征在于:步骤一中的细粉混合物粒度为0.0001mm—0.044mm,0.044mm—0.074mm ,0.074 mm-1mm,1mm-3mm中的两个或两个以上的粒度区间。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811016114.XA CN108837121A (zh) | 2018-09-02 | 2018-09-02 | 一种治疗高尿酸的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811016114.XA CN108837121A (zh) | 2018-09-02 | 2018-09-02 | 一种治疗高尿酸的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108837121A true CN108837121A (zh) | 2018-11-20 |
Family
ID=64233979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811016114.XA Pending CN108837121A (zh) | 2018-09-02 | 2018-09-02 | 一种治疗高尿酸的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108837121A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110575533A (zh) * | 2019-09-12 | 2019-12-17 | 广东雪芝康生物科技有限公司 | 通过调节基因表达降尿酸治疗痛风的组合物及其制备方法 |
CN112790308A (zh) * | 2020-03-06 | 2021-05-14 | 海南北鸥生物能源开发有限公司 | 一种酒糟酵母多糖免疫营养饮品的制备方法 |
CN112826917A (zh) * | 2021-03-08 | 2021-05-25 | 北京汉方普惠健康科技有限公司 | 一种复方桑葚黄芪中药组合物及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007008965A (ja) * | 2006-10-23 | 2007-01-18 | Pola Chem Ind Inc | 育毛剤 |
CN104069391A (zh) * | 2014-07-15 | 2014-10-01 | 刘鸿生 | 一种治疗痛风和高尿酸血症的中药组合物及其制备方法 |
CN107823509A (zh) * | 2017-11-30 | 2018-03-23 | 云南露源野生真菌研究所(有限合伙) | 一种治疗痛风的中药口服液及其制备方法 |
CN108159377A (zh) * | 2018-01-29 | 2018-06-15 | 安徽省纽斯康生物工程有限公司 | 一种用于降尿酸的中药配方 |
-
2018
- 2018-09-02 CN CN201811016114.XA patent/CN108837121A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007008965A (ja) * | 2006-10-23 | 2007-01-18 | Pola Chem Ind Inc | 育毛剤 |
CN104069391A (zh) * | 2014-07-15 | 2014-10-01 | 刘鸿生 | 一种治疗痛风和高尿酸血症的中药组合物及其制备方法 |
CN107823509A (zh) * | 2017-11-30 | 2018-03-23 | 云南露源野生真菌研究所(有限合伙) | 一种治疗痛风的中药口服液及其制备方法 |
CN108159377A (zh) * | 2018-01-29 | 2018-06-15 | 安徽省纽斯康生物工程有限公司 | 一种用于降尿酸的中药配方 |
Non-Patent Citations (2)
Title |
---|
HHL1011: "青年女性高尿酸血症", 《爱爱医医学网》 * |
梅全喜等: "《现代中药药理与临床应用手册》", 31 October 2016, 中国中医药出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110575533A (zh) * | 2019-09-12 | 2019-12-17 | 广东雪芝康生物科技有限公司 | 通过调节基因表达降尿酸治疗痛风的组合物及其制备方法 |
CN112790308A (zh) * | 2020-03-06 | 2021-05-14 | 海南北鸥生物能源开发有限公司 | 一种酒糟酵母多糖免疫营养饮品的制备方法 |
CN112826917A (zh) * | 2021-03-08 | 2021-05-25 | 北京汉方普惠健康科技有限公司 | 一种复方桑葚黄芪中药组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109674958B (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
CN102895320A (zh) | 一种防治高尿酸血症、痛风药食两用配方及制剂 | |
CN108837121A (zh) | 一种治疗高尿酸的中药组合物及其制备方法 | |
CN103933224B (zh) | 一种治疗痛风的中药组合物 | |
CN102362970B (zh) | 一种改善胃肠道功能的中药组合物及其制备工艺 | |
CN108887444A (zh) | 一种降尿酸的保健茶及其制备方法 | |
WO2008061447A1 (fr) | Médicament pour traiter l'eczéma et procédés d'application cutanée de ce médicament | |
CN102860505A (zh) | 一种具有辅助保护胃粘膜功能的朝医保健食品组合物及其制备方法和用途 | |
CN112076170A (zh) | 具有通便功能的片剂 | |
CN105287748B (zh) | 治疗高尿酸血症的中药制剂及其制备方法 | |
CN106070783A (zh) | 一种薏米祛湿茶的生产工艺 | |
CN102293928A (zh) | 治疗高尿酸血症及痛风性关节炎的中药组合物及其制备方法与应用 | |
CN100333758C (zh) | 一种抗痛风中药的组合物及其制备方法 | |
CN110051817A (zh) | 一种降低尿酸的中药组合及其应用 | |
CN104107308B (zh) | 一种治疗痔疮的药物及其制备方法 | |
CN111053859B (zh) | 降低尿酸的中药组合物及其制备方法和应用 | |
CN103932176B (zh) | 一种具有辅助降血脂功能的保健食品组合物及其制备方法和用途 | |
CN110090253B (zh) | 一种天然植物降脂组合物及其制备方法 | |
CN104288527B (zh) | 一种用于治疗糖尿病的中药组合物及其制备方法与应用 | |
CN113621461A (zh) | 一种通络降糖护肝酒及其制备方法 | |
CN104606571A (zh) | 一种生津止渴鲜菠菜根代茶饮及制备方法 | |
CN114767794B (zh) | 一种治疗动脉斑块的中药 | |
CN106620367A (zh) | 一种治疗膀胱结石的中药缓释胶囊及制备方法 | |
CN101164595A (zh) | 一种治疗厌食症的中药 | |
CN105194676A (zh) | 一种治疗高脂血症的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190131 Address after: 518000, 1001, 10th floor, Jiaye Plaza, 2055 Bixin Road, Longgang Street, Longgang District, Shenzhen City, Guangdong Province Applicant after: Doctor Biotechnology (Shenzhen) Co., Ltd. Address before: 453634 Jitun Town, Huixian City, Xinxiang City, Henan Province Applicant before: Liu Deping |
|
TA01 | Transfer of patent application right | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181120 |
|
WD01 | Invention patent application deemed withdrawn after publication |